Nuclear Medicine

Publications

List of Publications

  1. Enke JS, Barton AK, Kimura K, Calais J, Unterrainer L, Volkmann E. Fibroblast Activation Protein-Directed PET: Expanding FAPI Beyond Cancer. AJR Am J Roentgenol. Published online September 23, 2026. PMID: 42776577
  2. Ells Z, Hempel L, Ells J, Wu M, Scheifele M, Schoell M, Siegmund SC, Zacherl M, Werner RA, Calais J, Dahlbom M, Böning G, Holzgreve A, Delker A, Unterrainer LM. Influence of increased injected activities up 9.0 GBq [177Lu]Lu-PSMA-I&T on absorbed doses to lesions and kidneys. EJNMMI Phys. 2026;13(1). Published September 11, 2026. PMID: 42726377
  3. Civan C, Karpinski MJ, Darr C, Selvamoorthy T, Rennau LM, Hoberück S, Miederer M, Hölscher T, Bögemann M, Schäfers M, Rauscher I, Güven O, Calais J, Kimura K, Ufton D, Miszczyk M, Hofman MS, Hope TA, Kesch C, Herrmann K, Hadaschik B, Eiber M, Fendler WP, Rahbar K. PSMA-PET Tumor Volume Stratifies Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol Focus. Published online September 9, 2026. PMID: 42716860
  4. Jafarvand M, Farolfi A, Mei R, Djaileb L, Benz M, Chung A, Brisbane W, Marks L, Grogan T, Gafita A, Theus L, Nguyen AT, Czernin J, Calais J. PSMA PET Imaging for Prostate Cancer Recurrence After Minimally Invasive Focal Therapy: A Single-Center Retrospective Study. J Nucl Med. Published online August 20, 2026. doi:10.2967/jnumed.125.271556. PMID: 42624652
  5. Iravani A, Gulati R, Miyaoka R, Reiger AC, Chen DL, Kumar M, Erickson M, Nega K, Meyer C, Lira S, Seo Y, Flavell RR, Pritchard CC, Haffner MC, Nadal Rios R, Sunkara R, Khan HM, Yezefski T, Raychaudhuri R, Hsieh AC, Grivas P, Cheng HH, Yu EY, Schweizer MT, Nelson PS, Czernin J, Hope TA, Calais J. Clinical Trial Protocol for LPS-Boost: Intensified [177Lu]Lu-PSMA-617 Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer with Low PSMA-Expressing Disease. J Nucl Med. Published online August 13, 2026. PMID: 42595485
  6. Ells Z, Meyer C, Masri K, Ryhiner M, Sennung D, Kimura K, Mirando D, Tworowska I, Esfandiari R, Allen-Auerbach MS, Lassmann M, Herrmann K, Eiber M, Fendler WP, Delpassand E, Czernin J, Dahlbom M, Calais J. Tumor and Organ Dose Estimates from 177Lu-PSMA-617 Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Results from the RESIST-PC Phase 2 Trial. J Nucl Med. Published online July 30, 2026. doi:10.2967/jnumed.126.272574. PMID: 42532646
  7. Takashima ME, Kwon O, Ells Z, Li VR, Sawicki C, Schwartz RW, Ahn SH, Hyun M, Idrissou MB, Berg TJ, Clark PA, Lawless M, Besemer A, Bradshaw T, Perlman S, Jin W, Antonelli M, Adeniyi AO, Haasch CD, Chen T, Wang Y, Kumari R, Hernandez RT, Weichert J, Belanger AP, Ong I, Floberg J, Meyer C, Kishan AU, Calais J, Bednarz B, Morris ZS. Intratumoral dose heterogeneity promotes adaptive anti-tumor immunity and predicts clinical response to radiopharmaceutical therapy. bioRxiv (preprint). Posted July 30, 2026. PMID: 42539316
  8. Ells Z, Meyer C, Kimura K, Wilhalme H, Cao M, Ludwig VB, Unterrainer LM, Sennung D, Nabong R, Felix C, Valle LF, Daley A, Czernin J, Dahlbom M, Kishan AU, Calais J. Dosimetry Analysis of 177Lu-PSMA-I&T in Patients with Low-Volume Oligometastatic Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the LUNAR Trial. J Nucl Med. 2026;67(7):1125-1131. doi:10.2967/jnumed.125.271467. PMID: 41927282
  9. Kimura K, Livhits MJ, Laklouk IA, Gupta PK, Allen-Auerbach MS, Salavati A, Ruchalski KL, Benz MR, Calais J. [68Ga]Ga-FAPI-46 PET/CT in Adrenocortical Neoplasm, Oncocytic Type. J Nucl Med. 2026;67(7):1170-1171. PMID: 41887739
  10. Zahner J, Delker A, Ells Z, Nikolic AA, Holzgreve A, Siegmund SC, Tiling M, Zacherl MJ, Berg E, Aydogdu CD, Dierks A, Unterrainer M, Böning G, Stief C, Calais J, Lapa C, Werner RA, Casuscelli J, Unterrainer LM. Effects of androgen receptor signaling inhibitors on absorbed doses in mCRPC patients undergoing [177Lu]Lu-PSMA-617 or [177Lu]Lu-PSMA-I&T therapy: dosimetry results. Eur J Nucl Med Mol Imaging. Published online June 11, 2026. PMID: 42274762
  11. Nikitas J, Holzgreve A, Juarez J, Kimura K, Lira S, Alam H, Contreras M, Theus L, Nguyen AT, Ells Z, Zhu S, Grogan T, Elashoff DA, Unterrainer LM, Dahlbom M, Allen-Auerbach M, Czernin J, Calais J. Phase 2 Prospective Trial of Retreatment with [177Lu]Lu-PSMA-617 Molecular Radiotherapy for Metastatic Castration-Resistant Prostate Cancer—RE-LuPSMA. J Nucl Med. 2026;67(5):674-680. doi:10.2967/jnumed.125.271231. PMID: 41679923
  12. Holzgreve A, Calais J. Virchow Node in Prostate Cancer. Radiol Imaging Cancer. 2026;8(3):e250681. PMID: 41931017
  13. Kimura K, Murthy V, Voter AF, Solnes LB, Moradi Tuchayi A, Yadav S, Theus L, Nguyen A, Ludwig V, Holzgreve A, Unterrainer LM, Grogan TR, Czernin J, Hope TA, Gafita A, Calais J. PSMA PET/CT–Derived Indicators and Outcomes After [177Lu]Lu-PSMA-617: A Multicenter Retrospective Analysis from the U.S. Expanded-Access Program. J Nucl Med. 2026;67(5):731-738. doi:10.2967/jnumed.125.270789. PMID: 41679922
  14. Karpinski MJ, Civan C, Rauscher I, Güven O, Eiber M, Hoberück S, Miederer M, Bundschuh RA, Hölscher T, Calais J, Theus L, Nguyen AT, Scholtissek H, Lapa C, Di Giorgio A, Farolfi A, Ufton D, Drzezga A, Kunikowska J, Pelka K, Evangelista L, Bauman G, Alçin G, Beintner-Skawran S, Rohani MFM, Miksch J, Hüsing A, Kesch C, Herrmann K, Stuschke M, Umutlu L, Gafita A, Hofman MS, Hope TA, Goffin K, Kind F, Pizzuto DA, Soeterik TFW, Kömek H, Emmett L, Vondrak A, Pinter T, Lanfranchi F, Bauckneht M, Unterrainer LM, Holzgreve A, Bjartell A, Trägårdh E, Rasul S, Miszczyk M, Bögemann M, Rodriguez SantAnna Jauregui N, Schäfers M, Rahbar K, Hadaschik BA, Fendler WP; PROMISE Registry Group. New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study. Lancet Oncol. 2026;27(4):480-490. PMID: 41819113
    1. ASCO Post: New Prostate Cancer Risk Classification With PSMA-PET
    2. Diagnostic Imaging: Can PSMA PET Reinvent Risk Stratification for Prostate Cancer?
    3. UroToday: Beyond the Abstract – PPP3
  15. Mercier A, De Leiris N, Calais J, Ludwig VB, Farolfi A, Gafita A, Djaileb L. PSMA/FDG discordance: 24-hour [177Lu]-PSMA-617 SPECT versus 60-minute [68Ga]-PSMA-11 PET. Eur J Nucl Med Mol Imaging. 2026;53(4):2195-2196. doi:10.1007/s00259-025-07482-x. PMID: 40702229
  16. Murthy V, Kimura K, Theus L, Nguyen A, Grogan TR, Lokre O, Perk T, Rettig MB, Drakaki A, Shen J, Thin P, Nguyen K, Lira S, Nabong RM, Gardner L, Gonzalez BD, Gafita A, Czernin J, Calais J. Linking Baseline PSMA PET-Derived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [177Lu]Lu-PSMA-617: A Single-Center Retrospective Study. J Nucl Med. 2026;67(2):246-252. PMID: 41344853
  17. Holzgreve A, Unterrainer LM, Flores K, Lam EC, Mona CE, Czernin J, Shuch BM, Sisk AE, Calais J. FAP Expression in Renal Tumors Assessed by [68Ga]Ga-FAPI-46 PET Imaging and FAP Immunohistochemistry: A Case Series of Six Patients from the Prospective Exploratory Trial NCT04147494. J Nucl Med. 2026;67(1):49-52. doi:10.2967/jnumed.125.270346. PMID: 41101974
  18. Holzgreve A, Mona CE, Kimura K, Li X, Zhu Y, Tseng HR, Lee JK, Drakaki A, Garraway IP, Rettig MB, Calais J, Salavati A. Liquid Biopsy of Circulating Tumor Cells and DNA in the Context of PSMA Radiopharmaceutical Therapy. J Nucl Med. 2026;67(1):12-14. PMID: 41233144
  19. Kishan AU, Valle LF, Wilhalme H, Felix C, Nabong R, Juarez-Casillas JE, Flores K, Ma TM, Ludwig V, Nakayama M, Ells Z, Dahlbom M, Lauria M, Meyer C, Cao M, Weidhaas JB, Telesca D, McGreevy K, Nickols NG, Karasik D, Parmisano S, Basehart TV, Brisbane W, Marks L, Rettig MB, Reiter RE, Boutros PC, Allen-Auerbach M, Czernin J, Steinberg ML, Calais J. 177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study. J Clin Oncol. 2025;43(36):3812-3821. doi:10.1200/JCO-25-01553. PMID: 41223345
    1. UCLA Health Newsroom: New therapy delays progression of recurrent prostate cancer
    2. ASCO Post: Addition of Neoadjuvant LuPSMA PNT2002 to SBRT in Oligorecurrent Prostate Cancer
    3. VJOncology: ESMO 2025 | LUNAR: neoadjuvant 177Lu-PSMA and SBRT in oligometastatic HSPC
  20. Murthy V, Kimura K, Theus L, Nguyen A, Lokre O, Perk T, Thin P, Nguyen K, Ludwig V, Chen L, Gafita A, Czernin J, Calais J. Prognostic Value of AI-Assisted Lesion Tracking on End-of-Treatment PSMA PET in mCRPC Patients Treated with 177Lu-PSMA: A Retrospective, Single-Center Study. J Nucl Med. 2025;66(11):1690-1694. doi:10.2967/jnumed.125.269971. PMID: 40998723
  21. Karpinski MJ, Rahbar K, Bögemann M, Nikoukar LR, Schäfers M, Hoberück S, Miederer M, Hölscher T, Rasul S, Miszczyk M, Lanfranchi F, Bauckneht M, Pfob CH, Kind F, Goffin K, Hüsing A, Kesch C, Herrmann K, Stuschke M, Gafita A, Hüsing J, Calais J, Hofman MS, Hope TA, Miksch J, Soeterik TFW, Di Giorgio A, Farolfi A, Bjartell A, Trägårdh E, Unterrainer LM, Holzgreve A, Sheikh GT, Rauscher I, Eiber M, Hadaschik BA, Fendler WP. Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study. Eur Urol. 2025;88(5):484-495. doi:10.1016/j.eururo.2025.04.017. PMID: 40318933
  22. Holzgreve A, Delker A, Ells Z, Brosch-Lenz J, Unterrainer LM, Nikitas J, Zhu S, Contreras MM, Alam H, Nabong RM, Lira S, Vasilyev A, Chen L, Grogan T, Elashoff D, Meyer CA, Dahlbom M, Czernin J, Calais J. Randomized Phase 2 Trial of an Extended and Flexible Dosing Schedule of 177Lu-PSMA Molecular Radiotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT): Study Protocol. J Nucl Med. 2025;66(10):1639-1645. doi:10.2967/jnumed.125.269495. PMID: 40876952
  23. Juarez Casillas JE, Nikitas J, Rettig MB, Reiter RE, Lee A, Steinberg ML, Valle L, Kalbasi TR, Calais J, Czernin J, Eala MA, Tsai S, Kane N, Solanki AA, Sexton R, Duriseti S, Berenji GR, Aronson WJ, Garraway IP, Chang MG, Kwon R, Lee SP, Nickols NG, Kishan AU. Pooled Analysis of the SOLAR and SATURN Clinical Trials Comparing Progression of Synchronous Versus Metachronous Prostate-specific Membrane Antigen-defined Oligometastatic Prostate Cancer Following Systemic and Tumor-directed Therapy. Eur Urol Oncol. 2025;8(4):893-898. doi:10.1016/j.euo.2025.05.027. PMID: 40541485
  24. Unterrainer LM, Farolfi A, Grogan T, Hotta M, Djaileb L, Gafita A, Sonni I, Rettig MB, Rosar F, Ezziddin S, Denis CS, de Kouchkovsky I, Aggarwal R, Emmett L, Hope TA, Czernin J, Calais J. Early changes of PSMA PET expression after initiation of androgen receptor signaling inhibitors in CRPC: an international multicenter retrospective study. Eur J Nucl Med Mol Imaging. 2025;52(10):3700-3708. doi:10.1007/s00259-025-07178-2. PMID: 40137974
  25. Kuo PH, Calais J, Crosby M. PSMA PET Imaging in the Management of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Radioligand Therapy. Target Oncol. 2025;20(4):597-613. doi:10.1007/s11523-025-01151-7. PMID: 40418317
  26. Czernin J, Anderson CJ, Badawi RD, Barthel H, Bengel FM, Beyer T, Buvat I, Calais J, Dorbala S, Drzezga AE, Herrmann K, Hope TA, Jadvar H, Mankoff DA, Schelbert HR, Weber WA. Funding Reductions Threaten the Future of Medical Innovation. J Nucl Med. 2025;66(6):829. doi:10.2967/jnumed.125.270157
  27. Hotta M, Nguyen K, Thin P, Armstrong WR, Sonni I, Farolfi A, Steinberg M, Czernin J, Nickols NG, Kishan AU, Calais J. Kinetics of PSMA PET signal after radiotherapy in prostate cancer lesions: A single-center retrospective study. Radiother Oncol. 2025;207:110869. doi:10.1016/j.radonc.2025.110869
  28. Murthy V, Ludwig V, Gafita A, Hope TA, Calais J. The Role of PSMA PET Parameters as Biomarkers for Response to PSMA-Targeted Radiopharmaceutical Therapy. J Nucl Med. 2025;66(6):833-838. doi:10.2967/jnumed.124.268818
  29. Gafita A, Djaileb L, Calais J, Eiber M, Fendler WP. RECIP 1.0: A Roadmap for Clinical Implementation. J Nucl Med. 2025;66(5):673-675. doi:10.2967/jnumed.124.268730
  30. Ells Z, Ludwig V, Weiner AB, Kimura K, Farolfi A, Chamie K, Shirk J, Donin NM, Reiter R, Czernin J, Calais J (co-last author), Dahlbom M. A free method for patient-specific 3D-VR anatomical modeling for presurgical planning using DICOM images and open-source software. Methods. 2025;236:10-16. doi:10.1016/j.ymeth.2025.02.006
  31. Unterrainer LM, Hope TA, Fendler WP, Grogan T, Ndlovu H, Armstrong W, Barbato F, Benz MR, Rettig MB, Kishan AU, Sathekge M, Herrmann K, Czernin J, Calais J. Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET-An International Multicenter Retrospective Study. J Nucl Med. 2025;66(1):54-60. doi:10.2967/jnumed.124.268441. PMID: 39753363
    1. Urology Times: Addition of PSMA PET led to notable stage migration in mHSPC, study shows
  32. Holzgreve A, Armstrong WR, Clark KJ, Benz MR, Smith CP, Djaileb L, Gafita A, Thin P, Nickols NG, Kishan AU, Rettig MB, Reiter RE, Czernin J, Calais J. PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging. JAMA Netw Open. 2025;8(1):e2452971. doi:10.1001/jamanetworkopen.2024.52971. PMID: 39752157
    1. MedPageToday: PSMA-PET/CT Detects Metastatic Prostate Cancer Missed by Other Imaging
    2. AZO Optics: PSMA-PET Challenges Traditional Staging of High-Risk Prostate Cancer
    3. Renal + Urology News: PSMA-PET Detects Hidden Metastasis in Recurrent Prostate Cancer
    4. Inside Precision Medicine: Prostate Cancer Spread Missed By Conventional Imaging
    5. Urology Times: Conventional imaging may understage prostate cancer, new data suggest
    6. AuntMinnie: PSMA-PET/CT bests conventional imaging for prostate cancer diagnosis
    7. The University Network (TUN): Breakthrough PSMA-PET Imaging Reveals Hidden Metastases in Prostate Cancer
    8. The ASCO Post: Advanced Imaging May Uncover Hidden Metastases in High-Risk Prostate Cancer Cases
    9. Diagnostic Imaging: Study Emphasizes PSMA PET Staging of High-Risk, Hormone Sensitive Prostate Cancer
    10. OncoDaily: UCLA: Advanced imaging uncovered hidden metastases in high-risk prostate cancer cases
    11. UCLA Newsroom: Advanced imaging uncovers hidden metastases in high-risk prostate cancer cases
    12. Science Daily: Advanced imaging uncovers hidden metastases in high-risk prostate cancer cases
  33. Weiner AB, Ells Z, Meyer C, Dahlbom M, Sennung D, Varughese D, Ludwig VB, Carlucci G, Grant R, Czernin J, Calais J (co-last author), Reiter RE. Clinical Responses to Prostate-specific Membrane Antigen Radioguided Salvage Lymphadenectomy for Prostate Cancer Recurrence: Results from a Prospective Exploratory Trial. Eur Urol Open Sci. 2024;70:36-42. doi:10.1016/j.euros.2024.09.004. PMID: 39483519
  34. Sonni I, Weiner AB, Doddipalli S, Deol M, Ban D, Kim HO, Grogan T, Ahuja P, Barroso N, Zong Y, Soin P, Sisk A, Czernin J, Hsu W, Calais J, Reiter RE, Raman SS. Clinical, Pathologic, and Imaging Variables Associated with Prostate Cancer Detection by PSMA PET/CT and Multiparametric MRI. J Nucl Med. 2024;65(12):1923-1931. doi:10.2967/jnumed.124.268443
    1. UroToday: Clinical, Pathologic, and Imaging Variables Associated with Prostate Cancer Detection by PSMA PET/CT and Multiparametric MRI
  35. Huang RR, Zuo C, Mona CE, Holzgreve A, Morrissey C, Nelson PS, Brady L, True L, Sisk A, Czernin J, Calais J, Ye H. FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study. J Nucl Med. 2024;65(12):1952-1958. doi:10.2967/jnumed.124.268037. PMID: 39477498
    1. UroToday: FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study
  36. Weiner AB, Agrawal R, Wang NK, Sonni I, Li EV, Arbet J, Zhang JJH, Proudfoot JA, Hong BH, Davicioni E, Kane N, Valle LF, Kishan AU, Pra AD, Ghadjar P, Sweeney CJ, Nickols NG, Karnes RJ, Shen J, Rettig MB, Czernin J, Ross AE, Lee Kiang Chua M, Schaeffer EM, Calais J, Boutros PC, Reiter RE. Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naïve Prostate Cancer. Eur Urol. 2024;86(6):579-587. doi:10.1016/j.eururo.2024.09.005. PMID: 39294048
    1. Urology Times: PSMA levels linked to tumor biology, treatment sensitivity in treatment-naïve prostate cancer
  37. Hotta M, Kim GHJ, Rerkpichaisuth V, Teng PY, Armstrong WR, Carlucci G, Dahlbom M, Abtin F, Lari SM, Fishbein GA, Czernin J, Volkmann ER, Weigt SS, Calais J. Correlation of FAPI PET Uptake with Immunohistochemistry in Explanted Lungs from Patients with Advanced Interstitial Lung Disease. J Nucl Med. 2024;65(11):1789-1794. doi:10.2967/jnumed.124.268351. PMID: 39362770
  38. Murthy V, Voter AF, Nguyen K, Allen-Auerbach M, Chen L, Caputo S, Ledet E, Akerele A, Moradi Tuchayi A, Lawhn-Heath C, Wang T, Carducci MA, Pomper MG, Paller CJ, Czernin J, Solnes LB, Hope TA, Sartor O, Calais J (co-last author), Gafita A. Efficacy and Toxicity of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data. J Nucl Med. 2024;65(11):1740-1744. doi:10.2967/jnumed.124.267816. PMID: 39327018
    1. UroToday: Efficacy and Toxicity of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data
  39. Nikitas J, Gafita A, Benz MR, Djaïleb L, Farolfi A, Hotta M, Sonni I, Alano R, Rettig M, Shen J, Armstrong W, Grogan T, Liu S, Czernin J, Calais J. Phase 2 trial of PSMA PET CT versus planar bone scan and CT in prostate cancer patients progressing while on androgen deprivation therapy. Sci Rep. 2024;14(1):24411. doi:10.1038/s41598-024-75589-6. PMID: 39420060
    1. Urology Times: Jeremie Calais, MD, highlights study of PSMA-PET vs bone scan in metastatic prostate cancer
  40. Thin P, Hotta M, Gafita A, Grogan T, Czernin J, Calais J (co-last author), Sonni I. Clinical Factors That Influence Repeat 68Ga-PSMA-11 PET/CT Scan Positivity in Patients with Recurrent Prostate Cancer Under Observation After a Negative 68Ga-PSMA-11 PET/CT Scan: A Single-Center Retrospective Study. J Nucl Med. 2024;65(10):1571-1576. doi:10.2967/jnumed.124.267591. PMID: 39168522
    1. UroToday: Clinical Factors That Influence Repeat 68Ga-PSMA-11 PET/CT Scan Positivity in Patients with Recurrent Prostate Cancer Under Observation After a Negative 68Ga-PSMA-11 PET/CT Scan: A Single-Center Retrospective Study
  41. Nikitas J, Castellanos Rieger A, Farolfi A, Seyedroudbari A, Kishan AU, Nickols NG, Steinberg ML, Valle LF, Rettig M, Czernin J, Calais J. Prostate-Specific Membrane Antigen PET/CT-Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2024;65(9):1387-1394. doi:10.2967/jnumed.124.267922. PMID: 39089811
    1. UroToday: Prostate-Specific Membrane Antigen PET/CT-Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer
    2. Diagnostic Imaging: Can Targeted PSMA PET/CT-Guided Radiotherapy Have an Impact for Oligometastatic Prostate Cancer?
  42. Maliha PG, Hotta M, Farolfi A, Grogan T, Alano R, Limon A, Lam E, Carlucci G, Bahri S, Salavati A, Benz M, Silverman D, Gupta P, Quon A, Allen-Auerbach M, Czernin J, Calais J. FAPI PET uptake patterns after invasive medical interventions: a single center retrospective analysis. Eur J Nucl Med Mol Imaging. 2024;51(11):3373-3385. doi:10.1007/s00259-024-06733-7
  43. Emmett L, Papa N, Hope TA, Fendler W, Calais J, Burger I, Eiber M, Barbato F, Moon D, Counter W, John N, Xue A, Franklin A, Thompson J, Rasiah K, Frydenberg M, Yaxley J, Buteau J, Agrawal S, Ho B, Nguyen A, Liu V, Lee J, Woo H, Hsiao E, Sutherland T, Perry E, Stricker P, Hofman MS, Kasivisvanathan V, Roberts M, Murphy D. Beyond Prostate Imaging Reporting and Data System: Combining Magnetic Resonance Imaging Prostate Imaging Reporting and Data System and Prostate-Specific Membrane Antigen-Positron Emission Tomography/Computed Tomography PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer. J Urol. 2024;212(2):299-309. doi:10.1097/JU.0000000000004010. PMID: 38758680
  44. Ells Z, Grogan TR, Czernin J, Dahlbom M, Calais J. Dosimetry of [177Lu]Lu-PSMA-Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Metaanalysis. J Nucl Med. 2024;65(8):1264-1271. PMID: 38960712
  45. Ludwig V, Maliha PG, Shen J, Tonnelet D, Raman S, Litwin MS, Calais J. [68Ga]Ga-FAPI-46 False-Positive Uptake After Chemotherapy in Nonseminomatous Germ Cell Tumor Metastatic Lesions. J Nucl Med. 2024;65(8):1328-1329. PMID: 38664018
  46. Nikitas J, Subramanian K, Gozal NB, Ricaurte-Fajardo A, Li E, Proudfoot JA, Davicioni E, Marciscano AE, Osborne JR, Barbieri CE, Armstrong WR, Smith CP, Valle LF, Steinberg ML, Boutros PC, Nickols NG, Rettig MB, Reiter R, Weiner AB, Calais J, Czernin J, Ross AE, Kim EH, Nagar H, Kishan AU. Transcriptomic Profiling of Primary Prostate Cancers and Nonlocalized Disease on Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: A Multicenter Retrospective Study. JCO Precis Oncol. 2024;8:e2400161. doi:10.1200/PO.24.00161. PMID: 39013135
  47. Nikitas J, Lam E, Booker KA, Fendler WP, Eiber M, Hadaschik B, Herrmann K, Hirmas N, Lanzafame H, Stuschke M, Czernin J, Steinberg ML, Nickols NG, Kishan AU, Calais J. Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial). J Nucl Med. 2024;65(7):1076-1079. doi:10.2967/jnumed.123.267004. PMID: 38664019
  48. Armstrong WR, Kishan AU, Booker KM, Grogan TR, Elashoff D, Lam EC, Clark KJ, Steinberg ML, Fendler WP, Hope TA, Nickols NG, Czernin J, Calais J. Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774). Eur Urol. 2024;86(1):52-60. doi:10.1016/j.eururo.2024.01.012
    1. AuntMinnie: PSMA-PET helps plan treatment in men with relapsed prostate cancer
  49. Gafita A, Djaileb L, Rauscher I, Fendler WP, Hadaschik B, Rowe SP, Herrmann K, Solnes LB, Calais J, Rettig MB, Weber M, Farolfi A, Benz MR, Eiber M. RECIP 1.0 Predicts Progression-Free Survival After [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2024;65(6):917-922. doi:10.2967/jnumed.123.267234. PMID: 38637143
  50. Nikitas J, Rettig M, Shen J, Reiter R, Lee A, Steinberg ML, Valle LF, Sachdeva A, Romero T, Calais J, Czernin J, Nickols NG, Kishan AU. Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial. Eur Urol. 2024;85(6):517-520. doi:10.1016/j.eururo.2024.01.021
  51. Weber M, Fendler WP, Ravi Kumar AS, Calais J, Czernin J, Ilhan H, Saad F, Kretschmer A, Hekimsoy T, Brookman-May SD, Mundle SD, Small EJ, Smith MR, Perez PM, Hope TA, Herrmann K, Hofman MS, Eiber M, Hadaschik BA. Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study. Eur Urol. 2024;85(6):511-516. doi:10.1016/j.eururo.2024.01.019. PMID: 38490855
  52. Farolfi A, Armstrong WR, Djaileb L, Gafita A, Hotta M, Allen-Auerbach M, Unterrainer LM, Fendler WP, Rettig M, Eiber M, Hofman MS, Hadaschik B, Herrmann K, Czernin J, Calais J, Benz MR. Differences and Common Ground in 177Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers. J Nucl Med. 2024;65(3):438-445. doi:10.2967/jnumed.123.266391
  53. Emmett L, Papa N, Counter W, Calais J, Barbato F, Burger I, Eiber M, Roberts MJ, Agrawal S, Franklin A, Xue A, Rasiah K, John N, Moon D, Frydenberg M, Yaxley J, Stricker P, Wong K, Coughlin G, Gianduzzo T, Kua B, Ho B, Nguyen A, Liu V, Lee J, Hsiao E, Sutherland T, Perry E, Fendler WP, Hope TA. Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database. J Nucl Med. 2024;65(1):94-99. doi:10.2967/jnumed.123.266164. PMID: 38050155
  54. Maliha PG, Hotta M, Czernin J, Calais J. Characterizing Normal Variant [68Ga]Ga-FAPI-46 Uptake in the Epididymis. J Nucl Med. 2024;65(1):59-62. doi:10.2967/jnumed.123.266013. PMID: 37945382
  55. Djaïleb L, Armstrong WR, Thompson D, Gafita A, Farolfi A, Rajagopal A, Grogan TR, Nguyen K, Benz MR, Hotta M, Barbato F, Ceci F, Schwarzenböck SM, Unterrainer M, Zacho HD, Juarez R, Cooperberg M, Carroll P, Washington S, Reiter RE, Eiber M, Herrmann K, Fendler WP, Czernin J, Hope TA, Calais J. Presurgical 68Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial. Eur Urol. 2023;84(6):588-596. PMID: 37482512
    1. HealthDay: PSMA-PET Improves Prediction of Biochemical Recurrence in Prostate Cancer
    2. UCLA Health Newsroom: PSMA PET imaging improves accuracy of predicting prostate cancer recurrence
    3. Ecancer: PSMA PET imaging improves accuracy of predicting prostate cancer recurrence
    4. Urology Times: PSMA-PET shows value as a prognostic biomarker for recurrence in prostate cancer
  56. Meyer C, Stuparu A, Lueckerath K, Calais J, Czernin J, Slavik R, Dahlbom M. Tandem Isotope Therapy with 225Ac- and 177Lu-PSMA-617 in a Murine Model of Prostate Cancer. J Nucl Med. 2023;64(11):1772-1778. doi:10.2967/jnumed.123.265433. PMID: 37797974
  57. Koerber SA, Röhrich M, Walkenbach L, Liermann J, Choyke PL, Fink C, Schroeter C, Spektor AM, Herfarth K, Walle T, Calais J, Kauczor HU, Jaeger D, Debus J, Haberkorn U, Giesel FL. Impact of 68Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers. J Nucl Med. 2023;64(11):1712-1720. PMID: 37678928
    1. AuntMinnie: FAPI-PET/CT may improve treatment of cancer patients
  58. Murthy V, Gafita A, Thin P, Nguyen K, Grogan T, Shen J, Drakaki A, Rettig M, Czernin J, Calais J. Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with 177Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis. J Nucl Med. 2023;64(11):1737-1743. PMID: 37678927
  59. Hope TA, Benz M, Jiang F, Thompson D, Barbato F, Juarez R, Hernandez Pampaloni M, Allen-Auerbach M, Gupta P, Fendler WP, Calais J. Do Bone Scans Overstage Disease Compared with PSMA PET at Initial Staging? An International Multicenter Retrospective Study with Masked Independent Readers. J Nucl Med. 2023;64(11):1744-1747. PMID: 37591547
    1. UCSF: For Some Prostate Cancer Patients, PSMA PET May Be Better for Initial Staging of Disease
  60. Sonni I, Gafita A, Unterrainer LM, Alano RM, Lira S, Shen J, Drakaki A, Grogan T, Rettig MB, Czernin J, Calais J. Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with castrate-resistant prostate cancer: a prospective exploratory serial imaging study. EJNMMI Res. 2023;13(1):95. doi:10.1186/s13550-023-01048-4. PMID: 37902861
  61. Murthy V, Appiah-Kubi E, Nguyen K, Thin P, Hotta M, Shen J, Drakaki A, Rettig M, Gafita A, Calais J (co-last author), Sonni I. Associations of quantitative whole-body PSMA-PET metrics with PSA progression status under long-term androgen deprivation therapy in prostate cancer patients: a retrospective single-center study. Eur J Hybrid Imaging. 2023;7(1):18. doi:10.1186/s41824-023-00178-1. PMID: 37779132
  62. Kuo PH, Yoo DC, Avery R, Seltzer M, Calais J, Nagarajah J, Weber WA, Fendler WP, Hofman MS, Krause BJ, Brackman M, Kpamegan E, Ghebremariam S, Benson T, Catafau AM, Kendi AT. A VISION Substudy of Reader Agreement on 68Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177Lu-PSMA-617 Radioligand Therapy. J Nucl Med. 2023;64(8):1259-1265. PMID: 37230533
  63. Smith CP, Xiang M, Armstrong WR, Nickols NG, Steinberg ML, Reiter RE, Rettig M, Weiner AB, Shen J, Valle L, Czernin J, Calais J, Kishan AU. Patterns of Failure in Men With Radiorecurrent Prostate Cancer: A Post Hoc Analysis of 3 Prospective Gallium 68 Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Trials. Int J Radiat Oncol Biol Phys. 2023;116(5):1079-1084. PMID: 36863416
  64. Gafita A, Djaileb L, Rauscher I, Fendler WP, Hadaschik B, Rowe SP, Herrmann K, Calais J, Rettig M, Eiber M, Weber M, Benz MR, Farolfi A. Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate Cancer. Radiology. 2023;308(1):e222148. doi:10.1148/radiol.222148. PMID: 37432081
    1. AuntMinnie: Pluvicto patient response criteria validated
  65. Holzgreve A, Unterrainer M, Calais J, Adams T, Oprea-Lager DE, Goffin K, Lopci E, Unterrainer LM, Kramer KKM, Schmidt-Hegemann NS, Casuscelli J, Stief CG, Ricke J, Bartenstein P, Kunz WG, Mehrens D. Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial. Eur J Nucl Med Mol Imaging. Published online July 10, 2023. doi:10.1007/s00259-023-06332-y. PMID: 37428216
  66. Hotta M, Gafita A, Murthy V, Benz MR, Sonni I, Burger IA, Eiber M, Emmett L, Farolfi A, Fendler WP, Weber MM, Hofman MS, Hope TA, Kratochwil C, Czernin J, Calais J. PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [177Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study. J Nucl Med. 2023;64(7):1024-1029. doi:10.2967/jnumed.122.265242. PMID: 36997329 
    + Featured article of the month +
    1. Mirage News: New PSG Score Improves Patient Selection for PSMA Radiopharmaceutical Therapy
    2. SNMMI: Newly Developed PSG Score Improves Patient Selection for PSMA Radiopharmaceutical Therapy
    3. VJOncology: ASCO 2023 | PSMA PET ratio predicts response to [177Lu]PSMA radioligand therapy: a multicenter study
  67. Ma TM, Czernin J, Felix C, Alano R, Wilhalme H, Valle L, Steinberg ML, Dahlbom M, Reiter RE, Rettig MB, Cao M, Calais J, Kishan AU. LUNAR: a randomized Phase 2 study of 177 Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (clinical trial protocol). BJU Int. 2023;132(1):65-74. doi:10.1111/bju.15988. PMID: 36797449
  68. Crane JN, Graham DS, Mona CE, Nelson SD, Samiei A, Dawson DW, Dry SM, Masri MG, Crompton JG, Benz MR, Czernin J, Eilber FC, Graeber TG, Calais J, Federman NC. Fibroblast Activation Protein Expression in Sarcomas. Sarcoma. 2023;2023:2480493. PMID: 37333052
  69. Fizazi K, Herrmann K, Krause BJ, Rahbar K, Chi KN, Morris MJ, Sartor O, Tagawa ST, Kendi AT, Vogelzang N, Calais J, Nagarajah J, Wei XX, Koshkin VS, Beauregard JM, Chang B, Ghouse R, DeSilvio M, Messmann RA, de Bono J. Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24(6):597-610. doi:10.1016/S1470-2045(23)00158-4. PMID: 37269841
  70. Sonni I, Dal Pra A, O'Connell DP, Ells Z, Benz M, Nguyen K, Yoon SM, Deng J, Smith C, Grogan T, Nickols NG, Cao M, Kishan AU, Calais J. PSMA PET/CT-based Atlas for Prostatic Bed Recurrence after Radical Prostatectomy: Clinical Implications for Salvage Radiation Therapy Contouring Guidelines. J Nucl Med. 2023;64(6):902-909. doi:10.2967/jnumed.122.265025. PMID: 36759200
    1. SNMMI: PSMA PET Improves Decision Making for Prostate Cancer Treatment
  71. Gudenkauf LM, Chavez M, Maconi ML, Geiss C, Seyedroudbari A, Thin P, Hoogland AI, Nguyen K, Murthy V, Armstrong WR, Komrokji K, Oswald LB, Jim HSL, El-Haddad G, Fendler WP, Herrmann K, Cella D, Czernin J, Hofman MS, Dicker AP, Calais J, Tagawa ST, Gonzalez BD. Developing a novel patient reported outcomes measure for prostate cancer patients receiving radionuclide therapy. J Nucl Med. 2023;64(6):869-872. doi:10.2967/jnumed.122.264946
    1. Moffitt: Moffitt Researchers Develop Tool to Measure Patient Health and Well-Being after Radionuclide Therapy
  72. Smith CP, Proudfoot JA, Boutros PC, Reiter RE, Valle L, Rettig MB, Nickols NG, Feng FY, Nguyen PL, Nagar H, Spratt DE, Attard G, Weiner A, Weidhaas JB, Calais J, Ma TM, Davicioni E, Xiang M, Kishan AU. Transcriptomic Heterogeneity in High-risk Prostate Cancer and Implications for Extraprostatic Disease at Presentation on Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol Oncol. 2023;6(2):224-227. doi:10.1016/j.euo.2023.02.009. PMID: 36870853
  73. Hope TA, Allen-Auerbach M, Bodei L, Calais J, Dahlbom M, Dunnwald LK, Graham MM, Jacene HA, Heath CL, Mittra ES, Wright CL, Fendler WP, Herrmann K, Taïeb D, Kjaer A. SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors. J Nucl Med. 2023;64(2):204-210. PMID: 36725249
  74. Gafita A, Rauscher I, Weber M, Hadaschik B, Wang H, Armstrong WR, Tauber R, Grogan TR, Czernin J, Rettig MB, Herrmann K, Calais J, Weber WA, Benz M, Fendler WP, Eiber M. Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. J Nucl Med. 2022;63(11):1651-1658. PMID: 35422442 
    + SNMMI Alavi–Mandell Award 2023 +
  75. Meyer C, Prasad V, Stuparu A, Kletting P, Glatting G, Miksch J, Solbach C, Lueckerath K, Nyiranshuti L, Zhu S, Czernin J, Beer AJ, Slavik R, Calais J, Dahlbom M. Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225. EJNMMI Res. 2022;12(1):65. doi:10.1186/s13550-022-00935-6. PMID: 36182983
  76. Gafita A, Rauscher I, Fendler WP, Murthy V, Hui W, Armstrong WR, Herrmann K, Weber WA, Calais J, Eiber M, Weber M, Benz MR. Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria. Eur J Nucl Med Mol Imaging. 2022;49(12):4271-4281. doi:10.1007/s00259-022-05882-x. PMID: 35767071
  77. Hotta M, Gafita A, Czernin J, Calais J. Outcome of patients with PSMA-PET/CT screen failure by VISION criteria and treated with 177Lu-PSMA therapy: a multicenter retrospective analysis. J Nucl Med. 2022;63(10):1484-1488. PMID: 35273096
    1. Cancer Network: Low/No PSMA Expressing mCRPC Tumors Respond Poorly to 177Lu-PSMA-617 Therapy
  78. Mona CE, Benz MR, Hikmat F, Grogan TR, Lückerath K, Razmaria A, Riahi R, Slavik R, Girgis MD, Carlucci G, Kelly KA, French SW, Czernin J, Dawson DW, Calais J. Correlation of 68Ga-FAPi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of a Prospective Translational Exploratory Study. J Nucl Med. 2022;63(7):1021-1026. doi:10.2967/jnumed.121.262426. PMID: 34740953
    1. AuntMinnie: PET imaging lays foundation for new cancer therapies
  79. Sonni I, Felker ER, Lenis AT, Sisk AE, Bahri S, Allen-Auerbach MS, Armstrong WR, Suvannarerg V, Tubtawee T, Grogan T, Elashoff D, Eiber M, Raman SS, Czernin J, Reiter R, Calais J. Head-to-head comparison of 68Ga-PSMA-11 PET/CT and mpMRI with histopathology gold-standard in the detection, intra-prostatic localization and local extension of primary prostate cancer: results from a prospective single-center imaging trial. J Nucl Med. 2022;63(6):847-854. doi:10.2967/jnumed.121.262398 + Featured article of the month +
    1. Urology Times: PSMA and MRI for Early Prostate Cancer Detection
  80. Crompton J, Armstrong WR, Eckardt MA, Seyedroudbari A, Tap WD, Dry SM, Abt ER, Calais J, Herrmann K, Czernin J, Eilber FC, Benz MR. 18F-FLT PET/CT as a prognostic imaging biomarker of disease specific survival in patients with primary soft tissue sarcoma. J Nucl Med. 2022;63(5):708-712. doi:10.2967/jnumed.121.262502
  81. Abghari-Gerst M, Armstrong WR, Nguyen K, Calais J, Czernin J, Lin D, Jariwala N, Rodnick M, Hope TA, Hearn J, Montgomery JS, Alva A, Reichert ZR, Spratt DE, Johnson TD, Scott PJH, Piert M. A comprehensive assessment of 68Ga-PSMA-11 PET in biochemically recurrent prostate cancer: Results from a prospective multi-center study in 2005 patients. J Nucl Med. 2022;63(4):567-572. doi:10.2967/jnumed.121.262412
    1. Health Imaging: PSMA PET in UCLA Prostate Cancer Research
    2. DocWire News: 68Ga-PSMA-11 PET Specificity for Pelvic Nodal Metastases
  82. Morath V, Heider M, Mittelhäuser M, Rolbieski H, Stroh J, Calais J, Eiber M, Bassermann F, Weber WA. Initial evaluation of [18F]-FACBC for PET imaging of multiple myeloma. EJNMMI Res. 2022;12(1):4. doi:10.1186/s13550-022-00876-0. PMID: 35099620
  83. Ma TM, Roy S, Wu X, Mantz C, Fuller D, Miszczyk L, Napieralska A, Namysł-Kaletka A, Bagshaw HP, Buyyounouski MK, Glicksman R, Loblaw DA, Katz A, Upadhyaya SK, Nickols N, Steinberg ML, Philipson R, Aghdam N, Suy S, Pepin A, Collins SP, Boutros P, Rettig MB, Calais J, Wang M, Zaorsky N, Kishan AU. Refining the definition of biochemical failure in the era of stereotactic body radiation therapy for prostate cancer: The Phoenix definition and beyond. Radiother Oncol. 2022;166:1-7. doi:10.1016/j.radonc.2021.11.005. PMID: 34774650
  84. Ferdinandus J, Fendler WP, Farolfi A, Washington S, Mohamad O, Pampaloni MH, Scott PJ, Rodnick M, Viglianti BL, Eiber M, Herrmann K, Czernin J, Armstrong WR, Calais J, Hope TA, Piert M. PSMA PET validates higher rates of metastatic disease for European Association of Urology Biochemical Recurrence Risk Groups: an international multicenter study. J Nucl Med. 2022;63(1):76-80. doi:10.2967/jnumed.121.262821 + SNMMI Alavi–Mandell Award 2023 +
    1. Health Imaging: EUAs and Prostate Cancer Recurrence Risk
  85. Xiang M, Ma TM, Savjani R, Pollom EL, Karnes RJ, Grogan T, Wong JK, Motterle G, Tosoian JJ, Trock BJ, Klein EA, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Levin-Epstein R, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Huland H, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Alam R, Schwen Z, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Chong N, Kupelian PA, Rettig MB, Zaorsky NG, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Tilki D, Czernin J, Gafita A, Romero T, Calais J, Kishan AU. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. JAMA Netw Open. 2021;4(12):e2138550. PMID: 34902034
    1. Health Imaging: PSMA PET/CT and Prostate Cancer Outcomes
    2. EurekAlert!: UCLA-led study provides first indirect evidence that PSMA PET/CT surpasses conventional imaging in detecting occult prostate cancer spread and predicting long-term course and outcomes
    3. Medscape: PSMA PET/CT Validated as Imaging Modality in Prostate Cancer
  86. Giesel FL, Kratochwil C, Schlittenhardt J, Dendl K, Eiber M, Staudinger F, Kessler L, Fendler WP, Lindner T, Koerber SA, Cardinale J, Sennung D, Roehrich M, Debus J, Sathekge M, Haberkorn U, Calais J, Serfling S, Buck AL. Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients. Eur J Nucl Med Mol Imaging. 2021;48(13):4377-4385. PMID: 34137945
  87. Hope TA, Eiber M, Armstrong WR, Juarez R, Murthy V, Lawhn-Heath C, Behr SC, Zhang L, Barbato F, Ceci F, Farolfi A, Schwarzenböck SM, Unterrainer M, Zacho HD, Nguyen HG, Cooperberg MR, Carroll PR, Reiter RE, Holden S, Herrmann K, Zhu S, Fendler WP, Czernin J, Calais J. Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial. JAMA Oncol. 2021;7(11):1635-1642. doi:10.1001/jamaoncol.2021.3771
    1. Health Imaging: 'Practice changing': New research underscores clinical benefits of PSMA-PET for prostate cancer
    2. GU Oncology Now: 68Ga-PSMA-11 PET Has Specificity of 0.95 for Pelvic Nodal Metastases
  88. Calais J, Czernin J, Thin P, Gartmann J, Nguyen K, Armstrong WR, Allen-Auerbach M, Quon A, Bahri S, Gupta P, Gardner L, Dahlbom M, He B, Esfandiari R, Ranganathan D, Herrmann K, Eiber M, Fendler WP, Delpassand E. Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312). J Nucl Med. 2021;62(10):1447-1456. PMID: 34272322
  89. Calais J, Gafita A, Eiber M, Armstrong WR, Gartmann J, Thin P, Nguyen K, Lok V, Gosa L, Grogan T, Esfandiari R, Allen-Auerbach M, Quon A, Bahri S, Gupta P, Gardner L, Ranganathan D, Slavik R, Dahlbom M, Herrmann K, Delpassand E, Fendler WP, Czernin J. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort. J Nucl Med. 2021;62(10):1440-1446. PMID: 34016732